SAVE: Single-Administration Vaccine Enhancement

Lead Research Organisation: University of Edinburgh
Department Name: The Roslin Institute

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

It is well recognised that boosting of vaccine-induced immunity is required for long-term protection. A major challenge is to provide the necessary booster shots at the required intervals, particularly for non-housed animals. In this project, we will develop a materials technology platform that, contrary to existing devices, will ensure immediate and complete release of a vaccine booster at the optimal time point, from a capsule that is inserted under the skin at the time of the first vaccination.
To this end, we propose an implantable polymer capsule that contains the vaccine together with an osmolyte. The polymer will be selectively permeable to water so that the osmolyte drives the swelling of the capsule over time, ultimately resulting in rupture of the capsule and instant release of the payload. Unique to single administration vaccination strategies, our approach does not require co-processing of biomaterials and the active compound. This gives ample freedom for tuning the delay time and other properties of the device, enables the use of existing vaccine formulations, which will not be subjected to harsh processing conditions, and will be incorporated quantitatively.
Polymers with tailored water permeability will be synthesised and employed with stereolithography, a 3D printing technique, to prepare the capsules. The reproducibility and effectiveness of the release will be studied both in vitro and in vivo, and the device and its degradation products will be tested for toxicity and tissue response. While holding potential for a plethora of diseases, we will focus initially on bovine tuberculosis, a significant problem in UK cattle herds. The causative agent is also an important origin of human disease worldwide. If successful, this approach could save cost by eliminating the need to perform repeated vaccinations, as well as enable providing timely booster shots for animals without the need to recapture the animal or keep it in captivity.

Planned Impact

The following specific impacts are associated with this project:
1. Paving the way for commercialisation and manufacture of the device. Generating an interest for the technology with pharmaceutical companies should not commence only after the technology has been fully developed, but will start during the project in liaison with the knowledge transfer bodies at both Heriot-Watt University and The Roslin Institute. Initial market research and cost analysis of this technology vs. current options will be performed by a professional partner, to establish market potential of the technique under development.
2. Preparing vets, farmers and policy makers to facilitate the uptake of the upcoming new technology. We will gauge current opinions via survey, and develop an understanding and appreciation of the novel technology with stakeholders through targeted engagement including the Royal Highland Show, audience-targeted Open Days at the Roslin Innovation Centre, and veterinary and farming press. We have already initiated discussions with the Veterinary Medicines Directorate, part of the Department for Environment, Food & Rural Affairs (DEFRA), and the Medicines and Healthcare products Regulatory Agency (MHRA) to pre-empt potential obstacles on the route towards regulatory approvals and final application.
3. Expanding our collaborative network to start exploiting the wide range of potential applications, with a particular focus on Official Development Aid. As tuberculosis and vaccine delivery in general fit the Global Challenges particularly well, the collaborative network will be expanded through networking hubs to find overseas partners for follow-up projects, in which the novel technology will be tailored to regional needs and limitations.
4. Exploiting the opportunity this project brings to give the general public an appreciation for multidisciplinary research. Combining engineering and health, this project is ideal for showcasing multidisciplinary research, which will be performed through the Edinburgh Fringe Festival (Cabaret of Dangerous Ideas), the Edinburgh International Science festival and the Royal Highland Show.

Publications

10 25 50
 
Description The work aimed to develop a novel method for booster vaccination. We aimed to develop capsules that could be engineered to burst and release their contents (vaccines) into the skin at specified times after they were implanted. This would mean that booster vaccines would not need a second vet visit and instead the capsules would be placed into the skin at the first visit reducing costs and stress to the animals. This project was joint between Heriot-Watt and Edinburgh universities. At Heriot-Watt the team tested different types of polymers to generate the capsules, and different printing methods for these including 3D printing. They tested the burst time and release profiles from the capsules as well as testing whether the materials were toxic for cells. We also assessed whether the materials were likely to induce inflammation or cell death, and investigated the optimal methods for introducing the capsules into the skin. We identified a suitable polymer that would allow release of the vaccine at appropriate time points: this was shown to be non-toxic and the capsules could be inserted under the skin easily.
Exploitation Route We are intending to write follow on grants for submission to EPSRC and BBSRC. Applications for funding further aspects have been submitted as PhD projects. The information could be of interest to academics as well as those in the veterinary and human vaccine or pharmaceutical fields.
Sectors Agriculture, Food and Drink,Pharmaceuticals and Medical Biotechnology

 
Description Collaboration with Enesi Pharma Ltd (aVaxzipen Ltd) 
Organisation Enesi Pharma
Country United Kingdom 
Sector Private 
PI Contribution We have engaged with Enesi Pharma (now aVaxzipen Ltd) to further our research: this resulted in submission of two PhD proposals to Medical Research Scotland. Although these were unsuccessful we have established a strong collaborative partnership which will be important for further funding applications e.g. through IPA or LINK funding to UKRI. To date this has enabled knowledge exchange (under CDA).
Collaborator Contribution The partnership has led to the submission of two PhD project proposals and will form the basis for further funding applications. This has been in the form of knowledge exchange to date.
Impact Applications for PhD funding.
Start Year 2022
 
Description Designing new vaccine delivery systems for cattle 
Organisation Heriot-Watt University
Country United Kingdom 
Sector Academic/University 
PI Contribution This collaboration between Jayne Hope and Vicki Stone/Ferry Melchels at Heriot Watt University aims to develop implantable devices that will be engineered to release vaccine components under the skin of cattle at defined time points. This will enable prime-boost vaccination to be delivered in a single shot. The team at Heriot-Watt provide expertise in development of the device including materials expertise and 3D printing, whereas the team at Roslin provide in vitro and in vivo expertise to assess vaccine release, and immunogenicity.
Collaborator Contribution This collaboration between Jayne Hope and Vicki Stone/Ferry Melchels at Heriot Watt University aims to develop implantable devices that will be engineered to release vaccine components under the skin of cattle at defined time points. This will enable prime-boost vaccination to be delivered in a single shot. The team at Heriot-Watt provide expertise in development of the device including materials expertise and 3D printing, whereas the team at Roslin provide in vitro and in vivo expertise to assess vaccine release, and immunogenicity.
Impact This collaboration has led to a BBSRC grant funded in 2018 (BB/R008272/1). We appointed the first member of staff in September 2018 and a second member of staff will join the team in July 2019.
Start Year 2017